169 related articles for article (PubMed ID: 7095921)
41. Pharmacokinetics of the gastrokinetic agent mosapride citrate after single and multiple oral administrations in healthy subjects.
Sakashita M; Yamaguchi T; Miyazaki H; Sekine Y; Nomiyama T; Tanaka S; Miwa T; Harasawa S
Arzneimittelforschung; 1993 Aug; 43(8):867-72. PubMed ID: 8216445
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure.
Nagura Y; Kuno T; Yanai M; Maejima M; Okada K; Maeda H; Inoue M; Takahashi S; Hatano M
Nihon Jinzo Gakkai Shi; 1991 May; 33(5):539-43. PubMed ID: 1895553
[TBL] [Abstract][Full Text] [Related]
43. Disopyramide pharmacokinetics in the elderly after single oral administration.
Roberto P; Vitaliano B; Donatella P; Raffaella M; Sergio B; Gabriella C
Pharmacol Res Commun; 1988 Dec; 20(12):1025-34. PubMed ID: 3211990
[TBL] [Abstract][Full Text] [Related]
44. Disopyramide pharmacokinetics and bioavailability following the simultaneous administration of disopyramide and 14C-disopyramide.
Lima JJ; Haughey DB; Leier CV
J Pharmacokinet Biopharm; 1984 Jun; 12(3):289-313. PubMed ID: 6502472
[TBL] [Abstract][Full Text] [Related]
45. Single- and repeated-dose pharmacokinetics of intramuscular thiocolchicoside in healthy volunteers.
Weinling E; Sandouk P; Debray M; Scherrmann JM
Int J Clin Pharmacol Ther; 1999 Oct; 37(10):503-9. PubMed ID: 10543318
[TBL] [Abstract][Full Text] [Related]
46. Kinetics and dynamics of disopyramide and its dealkylated metabolite in healthy subjects.
Chiang WT; von Bahr C; Calissendorff B; Dahlqvist R; Emilsson H; Magnusson A; Schenck-Gustafsson K
Clin Pharmacol Ther; 1985 Jul; 38(1):37-44. PubMed ID: 4006374
[TBL] [Abstract][Full Text] [Related]
47. [Pharmacodynamics and pharmacokinetics of disopyramide phosphate].
Ol'binskaia LI; Tiukavkina NA; Kuz'mina MM; Beloborodov VL; Klimov AV
Farmakol Toksikol; 1985; 48(4):73-8. PubMed ID: 3930285
[TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics and tissue residue profiles of erythromycin in broiler chickens after different routes of administration.
Goudah A; Abo El Sooud K; Abd El-Aty AM
Dtsch Tierarztl Wochenschr; 2004 Apr; 111(4):162-5. PubMed ID: 15171602
[TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
[TBL] [Abstract][Full Text] [Related]
50. Clinical pharmacokinetics of disopyramide.
Siddoway LA; Woosley RL
Clin Pharmacokinet; 1986; 11(3):214-22. PubMed ID: 3524956
[TBL] [Abstract][Full Text] [Related]
51. Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man.
Hasselström J; Enquist M; Hermansson J; Dahlqvist R
Eur J Clin Pharmacol; 1991; 41(5):481-4. PubMed ID: 1761078
[TBL] [Abstract][Full Text] [Related]
52. Disopyramide kinetics in patients with acute myocardial infarction.
Ilett KF; Madsen BW; Woods JD
Clin Pharmacol Ther; 1979 Jul; 26(1):1-7. PubMed ID: 445953
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetics of etofylline after intravenous and oral administration to humans.
Zuidema J; Verhoeven J; Merkus FW
Int J Clin Pharmacol Ther Toxicol; 1981 Jul; 19(7):310-3. PubMed ID: 7263108
[TBL] [Abstract][Full Text] [Related]
54. Disopyramide: clinical indications, pharmacokinetics and laboratory assessment.
Taylor EH; Pappas AA
Ann Clin Lab Sci; 1986; 16(4):289-95. PubMed ID: 2427003
[TBL] [Abstract][Full Text] [Related]
55. Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Bredesen JE; Pike E; Lunde PK
Br J Clin Pharmacol; 1982 Nov; 14(5):673-6. PubMed ID: 7138747
[TBL] [Abstract][Full Text] [Related]
56. Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Bredesen JE; Kierulf P
Br J Clin Pharmacol; 1984 Nov; 18(5):779-84. PubMed ID: 6508986
[TBL] [Abstract][Full Text] [Related]
57. The protein binding of diazepam and N-demethyldiazepam in patients with poor renal function.
Kangas L; Kanto J; Forsström J; Iisalo E
Clin Nephrol; 1976 Mar; 5(3):114-8. PubMed ID: 1261102
[TBL] [Abstract][Full Text] [Related]
58. The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.
Ward JW; Kinghorn GR
J Int Med Res; 1976; 4(1 Suppl):49-53. PubMed ID: 1026529
[No Abstract] [Full Text] [Related]
59. Simultaneous determination of disopyramide and its mono-N-dealkyl metabolite in plasma and urine by high-performance liquid chromatography.
Charette C; McGilveray IJ; Mainville C
J Chromatogr; 1983 May; 274():219-30. PubMed ID: 6874823
[TBL] [Abstract][Full Text] [Related]
60. Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.
Rangno RE; Warnica W; Ogilvie RI; Kreeft J; Bridger E
J Int Med Res; 1976; 4(1 Suppl):54-8. PubMed ID: 1026530
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
